Hyun-Gyu Lee
Geen lopende functies
Vermogen: 4 M $ op 30-04-2024
Profiel
Hyun-Gyu Lee worked as a Director at Enlivex Therapeutics Ltd.
before obtaining a doctorate degree from Seoul National University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
13-09-2023 | 36 000 ( 0.55% ) | 4 M $ | 30-04-2024 |
Eerdere bekende functies van Hyun-Gyu Lee
Bedrijven | Functie | Einde |
---|---|---|
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Directeur/Bestuurslid | - |
Opleiding van Hyun-Gyu Lee
Seoul National University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |